Compounds > doripenem
Page last updated: 2024-08-25

doripenem and Critical Illness

doripenem has been researched along with Critical Illness in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's12 (92.31)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Flamm, R; Kaniga, K; Nandy, P; Samtani, MN1
Boonpeng, A; Chaijamorn, W; Charoensareerat, T; Pattharachayakul, S; Puchsaka, P; Pummangura, C; Srisawat, N1
Bulitta, JB; Dunlop, R; Hayashi, Y; Jarrett, P; Lassig-Smith, M; Lipman, J; Roberts, JA; Roberts, NA; Starr, T; Stuart, J; Udy, AA; Wallis, SC1
Abd Rahman, AN; Abdul-Aziz, MH; Lipman, J; Mat-Nor, MB; Roberts, JA; Staatz, CE; Sulaiman, H; Wallis, SC1
Barnett, AG; Diab, S; Fraser, JF; Fung, YL; Roberts, JA; Shekar, K; Wallis, SC1
Abraham, P; Chaar, M; Chester, K; Curzio, K; Huang, V; Lockwood, A; Lodise, TP; Morse, B; Pai, MP; Patka, J; Rabinovich, M; Rahbar, AJ; Salomone, J; Williams, B1
Ambrose, PG; Andes, DR; Bhavnani, SM; Van Wart, SA1
Goto, K; Hagiwara, S; Hidaka, S; Iwasaka, H; Noguchi, T1
Lin, R; Nandy, P; Samtani, MN1
Abe, T; Goto, K; Hagiwara, S; Hidaka, S; Nishida, T; Noguchi, T; Ohchi, Y; Shitomi, R; Yamamoto, S; Yasuda, N1
De Waele, JJ; Lipman, J; Paterson, DL; Roberts, JA; Udy, AA1
Aeinlang, N; Jaruratanasirikul, S; Jullangkoon, M; Kositpantawong, N; Wongpoowarak, W1
Lipman, J; Roberts, JA1

Trials

3 trial(s) available for doripenem and Critical Illness

ArticleYear
Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bayes Theorem; Carbapenems; Creatinine; Critical Illness; Cross Infection; Doripenem; Female; Humans; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nonlinear Dynamics; Pneumonia, Bacterial; Pyelonephritis; Renal Insufficiency; Urinary Tract Infections; Young Adult

2010
Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
    International journal of antimicrobial agents, 2012, Volume: 40, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Critical Illness; Doripenem; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Time Factors

2012
Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Critical care medicine, 2013, Volume: 41, Issue:2

    Topics: Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Cross Infection; Doripenem; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intensive Care Units; Male; Middle Aged; Monte Carlo Method; Obesity; Pneumonia, Bacterial

2013

Other Studies

10 other study(ies) available for doripenem and Critical Illness

ArticleYear
Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6

    Topics: Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method

2010
Doripenem dosing regimens in Asian critically ill patients with continuous renal replacement therapy.
    Journal of critical care, 2019, Volume: 52

    Topics: Acute Kidney Injury; Anti-Bacterial Agents; Body Weight; Continuous Renal Replacement Therapy; Critical Illness; Doripenem; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections

2019
Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:9

    Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Critical Illness; Doripenem; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Plasma; Young Adult

2014
Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Acinetobacter baumannii; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Doripenem; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Malaysia; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Prospective Studies; Pseudomonas aeruginosa; Sepsis; Survival Analysis

2016
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
    Critical care (London, England), 2015, Dec-15, Volume: 19

    Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illness; Doripenem; Echinocandins; Extracorporeal Membrane Oxygenation; Fluconazole; Gentamicins; Lipopeptides; Meropenem; Models, Theoretical; Sheep; Sheep, Domestic; Thienamycins; Vancomycin

2015
Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.
    Surgical infections, 2016, Volume: 17, Issue:6

    Topics: Adult; Anti-Bacterial Agents; Carbapenems; Critical Illness; Doripenem; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Sepsis; Wounds and Injuries

2016
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
    Diagnostic microbiology and infectious disease, 2009, Volume: 63, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Clinical Trials as Topic; Computer Simulation; Critical Illness; Doripenem; Female; Humans; Mice

2009
Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF).
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:1

    Topics: Aged; Aged, 80 and over; Carbapenems; Critical Illness; Doripenem; Female; Half-Life; Hemodiafiltration; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Renal Insufficiency

2010
Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2011, Volume: 131, Issue:9

    Topics: Aged; Aged, 80 and over; Carbapenems; Chromatography, High Pressure Liquid; Critical Illness; Doripenem; Female; Hemodiafiltration; Humans; Kidney Diseases; Male; Middle Aged; Severity of Illness Index; Time Factors

2011
What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
    International journal of antimicrobial agents, 2012, Volume: 39, Issue:6

    Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Critical Illness; Cross Infection; Doripenem; Humans; Kidney; Metabolic Clearance Rate; Pneumonia; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic

2012